Cytek Biosciences (CTKB) Competitors $3.44 -0.03 (-0.86%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.44 0.00 (0.00%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTKB vs. TXG, TRNS, EYPT, ALNT, LAB, AEHR, SENS, QSI, MASS, and QTRXShould you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), EyePoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Aehr Test Systems (AEHR), Senseonics (SENS), Quantum-Si (QSI), 908 Devices (MASS), and Quanterix (QTRX). These companies are all part of the "measuring and control equipment" industry. Cytek Biosciences vs. Its Competitors 10x Genomics Transcat EyePoint Pharmaceuticals Allient Standard BioTools Aehr Test Systems Senseonics Quantum-Si 908 Devices Quanterix Cytek Biosciences (NASDAQ:CTKB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Do analysts prefer CTKB or TXG? Cytek Biosciences currently has a consensus price target of $5.60, suggesting a potential upside of 62.79%. 10x Genomics has a consensus price target of $15.81, suggesting a potential upside of 46.64%. Given Cytek Biosciences' higher possible upside, research analysts plainly believe Cytek Biosciences is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytek Biosciences 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.2010x Genomics 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38 Is CTKB or TXG more profitable? Cytek Biosciences has a net margin of -5.05% compared to 10x Genomics' net margin of -29.90%. Cytek Biosciences' return on equity of -2.58% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets Cytek Biosciences-5.05% -2.58% -2.05% 10x Genomics -29.90%-25.40%-19.69% Does the MarketBeat Community favor CTKB or TXG? 10x Genomics received 44 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 50.00% of users gave 10x Genomics an outperform vote while only 43.14% of users gave Cytek Biosciences an outperform vote. CompanyUnderperformOutperformCytek BiosciencesOutperform Votes2243.14% Underperform Votes2956.86% 10x GenomicsOutperform Votes6650.00% Underperform Votes6650.00% Which has preferable earnings and valuation, CTKB or TXG? Cytek Biosciences has higher earnings, but lower revenue than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytek Biosciences$197.05M2.21-$12.15M-$0.09-38.2210x Genomics$624.66M2.12-$182.63M-$1.30-8.29 Which has more volatility & risk, CTKB or TXG? Cytek Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Does the media favor CTKB or TXG? In the previous week, 10x Genomics had 4 more articles in the media than Cytek Biosciences. MarketBeat recorded 6 mentions for 10x Genomics and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.01 beat 10x Genomics' score of 0.31 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in CTKB or TXG? 69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 10.3% of Cytek Biosciences shares are held by company insiders. Comparatively, 9.4% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryCytek Biosciences and 10x Genomics tied by winning 9 of the 18 factors compared between the two stocks. Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTKB vs. The Competition Export to ExcelMetricCytek BiosciencesAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$435.71M$4.59B$5.57B$8.63BDividend YieldN/A0.55%5.28%4.18%P/E Ratio-42.9925.0227.1420.06Price / Sales2.213.89411.98157.10Price / Cash206.1636.3438.2534.64Price / Book1.191.677.064.70Net Income-$12.15M-$82.28M$3.23B$247.88M7 Day Performance2.99%6.12%2.85%2.63%1 Month Performance13.91%11.47%9.06%6.36%1 Year Performance-44.34%-11.37%31.43%14.05% Cytek Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTKBCytek Biosciences2.1588 of 5 stars$3.44-0.9%$5.60+62.8%-45.9%$435.71M$197.05M-42.99500Positive NewsTXG10x Genomics4.2548 of 5 stars$10.09+7.1%$15.81+56.7%-50.0%$1.16B$624.66M-6.641,240Analyst ForecastHigh Trading VolumeTRNSTranscat2.9677 of 5 stars$76.68-1.7%$114.00+48.7%-40.2%$714.50M$278.42M41.45920Analyst RevisionEYPTEyePoint Pharmaceuticals2.4634 of 5 stars$8.93-0.1%$25.38+184.2%-6.5%$614.48M$56.04M-4.47120Positive NewsAnalyst RevisionGap UpALNTAllient2.9856 of 5 stars$33.36+4.6%$31.00-7.1%+32.9%$564.75M$516.06M37.911,950Positive NewsLABStandard BioTools2.7025 of 5 stars$1.08+1.9%$2.50+131.5%-54.2%$410.21M$169.69M-1.52620Positive NewsAEHRAehr Test Systems3.5984 of 5 stars$11.78+3.9%$25.00+112.2%-13.1%$350.70M$61.48M15.7190Positive NewsSENSSenseonics2.3586 of 5 stars$0.53+0.6%$1.55+192.5%+27.4%$346.73M$23.68M-4.0890Positive NewsQSIQuantum-Si2.9012 of 5 stars$1.71-1.7%$3.48+103.2%+20.5%$319.29M$3.44M-2.67150Positive NewsGap UpMASS908 Devices2.0448 of 5 stars$6.98+0.6%$5.33-23.6%+20.5%$250.31M$63.99M-3.9460Positive NewsAnalyst ForecastQTRXQuanterix3.2553 of 5 stars$5.06-5.8%$15.60+208.3%-63.3%$196.48M$133.92M-4.77460Insider TradeGap Up Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives EyePoint Pharmaceuticals Alternatives Allient Alternatives Standard BioTools Alternatives Aehr Test Systems Alternatives Senseonics Alternatives Quantum-Si Alternatives 908 Devices Alternatives Quanterix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTKB) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTKB Stock Free CTKB Stock Alerts